Dear Friends,
It’s an exciting time for TransCelerate BioPharma. In addition to the pioneering Initiatives we’re refining and developing, we also recently launched a new subsidiary: BioCelerate.
So… what is BioCelerate?
- BioCelerate was launched initially by six biopharmaceutical companies who are also TransCelerate Members – Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Novo Nordisk and Shionogi.
- While TransCelerate focuses on Clinical Development, BioCelerate sets it sights on the preclinical space, identifying and developing pragmatic and tangible solutions to improve efficiencies in preclinical research. BioCelerate’s first Initiative is Toxicology Data Sharing.
How will BioCelerate’s Toxicology Data Sharing Initiative drive change?
- Toxicology Data Sharing (TDS) is aimed at enabling access to a broader cross-company set of toxicology data.
- Motivated in part by the FDA’s 2011 Strategic Plan for Regulatory Science, which included an objective around modernizing toxicology, BioCelerate’s TDS Initiative will help with effective translation of nonclinical findings, and attempt to close critical gaps that exist in understanding the relationship between patient response and preclinical toxicology findings.
- We believe that by pooling toxicology information from each of the BioCelerate Member Companies, we can break through our data siloes and help all of us better determine risk.
In the meantime, we’d like to hear from you. What are you current pain points for preclinical studies? Take our mini questionnaire to give us your thoughts: Questionnaire
Throughout 2016, we’ll be providing updates on our progress. With the momentum and excitement behind both TransCelerate and BioCelerate, we are confident that our collective innovation will help bring new medicines to patients faster, and improve the health of people around the world.
Stay tuned for more updates on BioCelerate, and reach out to us at any time!
Best Regards,
The TransCelerate Team
|
|
|
|
